

Supplementary table 1. Indicative power

Sample Size	Power	Number <i>without</i> RVD	Number <i>with</i> RVD	Mortality in patients <i>without</i> RVD	Mortality in patients <i>with</i> RVD	Odds Ratio
120	80%	60	60	0.373	0.627	2.83
120	90%	60	60	0.354	0.646	3.33
150	80%	75	75	0.386	0.614	2.53
150	90%	75	75	0.369	0.631	2.92
120	80%	90	30	0.427	0.719	3.43
120	90%	90	30	0.417	0.749	4.17
150	80%	112	38	0.435	0.695	2.96
150	90%	112	38	0.426	0.722	3.50

Differences in mortality rates that could be detected at a 5% significance level for sample sizes of 120 and 150, and proportions of patients with RV dysfunction of 25% and 50%, assuming an overall mortality rate of 50%. RVD = Right Ventricular Dysfunction.

Supplementary Table 2. Determination of primary outcome				
RV dilatation	Septal flattening	Primary outcome	Included/excluded	n
Yes	Yes	Yes	Included	7
Yes	Unable to assess	Unknown	Excluded	0
Yes	No	No	Included	24
Unable to assess	No	No	Included	2
No	No	No	Included	74
No	Yes	No	Included	2
No	Unable to assess	No	Included	3
Unable to assess	Unable to assess	Unknown	Excluded	6

RV = Right Ventricle

Supplementary Table 3. Patient characteristics at ICU admission

		All (n=112)	RVD (n=33)	No RVD (n=79)	p-value
Age, years		59.2 (11.3)	60.7 (9.9)	58.5 (11.8)	0.326 [#]
Sex, Male		74 (66.1%)	22 (66.7%)	52 (65.8%)	>0.99 [†]
BMI, kg m ⁻²	<i>n (n missing)</i>	110 (2)	32 (1)	78 (1)	
		32.9 (7.1)	32.9 (6.7)	32.8 (7.3)	0.952 [#]
Ethnicity	White	100 (89.3%)	26 (78.8%)	74 (93.7%)	
	Non-white	12 (10.7%)	7 (21.2%)	5 (6.3%)	0.039 [†]
Time since symptom onset to intubation, days		11 [7, 16]	11.0 [7, 17]	10.5 [7.2, 14]	0.384 [‡]
Clinical frailty score	<i>n (n missing)</i>	111 (1)	33 (0)	78 (1)	
		2.4 (0.9)	2.4 (1)	2.3 (0.9)	0.930 [#]
APACHE II	<i>n (n missing)</i>	107 (5)	33 (0)	74 (5)	
		16.6 (5.8)	16.8 (5.1)	16.6 (6.2)	0.877 [#]
CCCC	<i>n (n missing)</i>	102 (10)	29 (4)	73 (6)	
		10.2 (2.7)	10.8 (1.9)	10.0 (3)	0.105 [#]
Comorbidities					
Smoking	Non-smoker	63 (56.2%)	22 (66.7%)	41 (51.9%)	
	Ex-smoker > 1 year	40 (35.7%)	10 (30.3%)	30 (38%)	0.293 [†]
	Current or within 1 year	9 (8%)	1 (3%)	8 (10.1%)	
Alcohol history	<i>n (n missing)</i>	110 (2)	33 (0)	77 (2)	
	None	34 (30.9%)	10 (30.3%)	24 (31.2%)	
	Minimal	57 (51.8%)	20 (60.6%)	37 (48.1%)	0.544 [†]
	Moderate	8 (7.3%)	1 (3%)	7 (9.1%)	
	Excess	11 (10%)	2 (6.1%)	9 (11.7%)	
Hypertension		38 (33.9%)	13 (39.4%)	25 (31.6%)	0.513 [†]
Coronary artery disease		11 (9.8%)	4 (12.1%)	7 (8.9%)	0.333 [†]
Diabetes		33 (29.5%)	9 (27.3%)	24 (30.4%)	0.823 [†]
Asthma		16 (14.3%)	4 (12.1%)	12 (15.2%)	0.775 [†]
COPD		10 (8.9%)	2 (6.1%)	8 (10.1%)	0.803 [†]
Treatments before intubation					
Intravenous corticosteroids		74 (66.1%)	25 (75.8%)	49 (62%)	0.193 [†]
Non-invasive ventilation		76 (67.9%)	22 (66.7%)	54 (68.4%)	>0.99 [†]
High flow nasal oxygen		65 (58%)	24 (72.7%)	41 (51.9%)	0.058 [†]
Awake self-proning		57 (50.9%)	19 (57.6%)	38 (48.1%)	0.411 [†]
Acute comorbidities since hospital admission					
New arrhythmias		17 (15.2%)	6 (18.2%)	11 (13.9%)	0.573 [†]
Confirmed or suspected	Radiologically confirmed	4 (3.6%)	4 (12.1%)	0 (0%)	
	Clinically suspected	5 (4.5%)	2 (6.1%)	3 (3.8%)	0.010 [†]
PTE	No	101 (90.2%)	27 (81.8%)	74 (93.7%)	
	Unknown	2 (1.8%)	0 (0%)	2 (2.5%)	
ACS		5 (4.5%)	2 (6.1%)	3 (3.8%)	0.630 [†]
Requirement for RRT		18 (16.1%)	6 (18.2%)	12 (15.2%)	0.779 [†]

RVD defined as RV dilatation *and/or* septal flattening

Data are presented as mean (SD), median [IQR] or n (%). Data are complete unless indicated by *n (n missing)*. P-values provided are for comparisons between RVD vs no RVD. # = Student's T-test. † = Fisher's Exact test. ‡ = Wilcoxon Mann-Whitney test.

RVD = Right Ventricular Dysfunction, BMI = Body Mass Index, APACHE = Acute Physiology And Chronic Health Evaluation, CCCC = Coronavirus Clinical Characterisation Consortium, COPD = Chronic Obstructive Pulmonary Disease, PTE = Pulmonary Thromboembolism, ACS = Acute Coronary Syndrome, RRT = Renal Replacement Therapy.

Supplementary Table 4. Clinical consequences

	All (n=112)	RVD (n=33)	No RVD (n=79)	p-value
<i>30-day follow-up</i>				
Death	53 (47.3%)	17 (51.5%)	36 (45.6%)	0.679 [†]
RRT	28 (25%)	9 (27.3%)	19 (24.1%)	0.879 [†]
Prone ventilation	55 (49.1%)	13 (39.4%)	42 (53.2%)	0.213 [†]
Referral for ECMO	15 (13.4%)	1 (3.0%)	14 (17.7%)	0.097 [†]

RVD defined as RV dilatation *and/or* septal flattening

Data are presented as n (%). Data are complete unless indicated by *n* (*n missing*). P-values provided are for comparisons between RVD vs no RVD. † = Fisher's Exact test.

RRT = Renal Replacement Therapy, ECMO = Extra Corporeal Membrane Oxygenation.

Supplementary Table 5. Patient characteristics on day of echocardiography

		All (n=112)	RVD (n=33)	No RVD (n=79)	p-value
Requirement for prone invasive ventilation since ICU admission		79 (70.5%)	28 (84.8%)	51 (64.6%)	0.061 [†]
SOFA score		7.9 (3)	8.8 (3.2)	7.6 (2.8)	0.048 [#]
Requirement for RRT on day of echo		15 (13.4%)	7 (21.2%)	8 (10.1%)	0.135 [†]
Lab Measurements					
Arterial Blood Gas					
[H⁺], nmol L⁻¹	<i>n (n missing)</i>	97 (15) 39 [35.8, 46]	29 (4) 40.9 [36, 49]	68 (11) 39 [34.8, 45]	0.230 [‡]
PaO₂, kPa		9.3 (1.2)	9.1 (1.3)	9.4 (1.2)	0.428 [#]
PaCO₂, kPa	<i>n (n missing)</i>	109 (3) 6.9 [5.9, 8]	33 (0) 7.0 [5.9, 7.9]	76 (3) 6.8 [5.9, 8]	0.929 [‡]
BE, mmol	<i>n (n missing)</i>	110 (2) 5.9 (6.5)	33 (0) 3.8 (6.4)	77 (2) 6.8 (6.3)	0.026 [#]
Bicarbonate, mmol L⁻¹	<i>n (n missing)</i>	109 (3) 31.8 (6.6)	33 (0) 30.0 (6.1)	76 (3) 32.5 (6.7)	0.063 [#]
Full Blood Count					
Haemoglobin, g dl⁻¹		11 (1.8)	10.7 (1.4)	11.2 (1.9)	0.127 [#]
Neutrophils, x10⁹ L⁻¹		10.5 [8.5, 14.9]	12.3 [8.9, 17.7]	10.3 [8.4, 13.6]	0.128 [‡]
Lymphocytes, x10⁹ L⁻¹		0.9 [0.5, 1.4]	0.9 [0.7, 1.5]	0.9 [0.4, 1.3]	0.239 [‡]
Platelets, x10⁹ L⁻¹		279.5 (109.5)	276.5 (105.7)	280.8 (111.7)	0.849 [#]
Inflammation					
CRP, mg L⁻¹		61.5 [11.8, 157.5]	72.0 [14, 178]	54.0 [11, 149]	0.375 [‡]
Coagulation					
D-Dimers, mg L⁻¹ FEU	<i>n (n missing)</i>	81 (31) 1264 [601, 2605]	27 (6) 1156 [504, 2822]	54 (25) 1373 [724.8, 2496]	0.745 [‡]
PT, seconds		12 [11, 13.2]	13 [11, 13]	12 [11, 13.2]	0.264 [‡]
APTT, seconds	<i>n (n missing)</i>	111 (1) 27 [25, 31]	33 (0) 29 [26, 31]	78 (1) 26 [24, 30]	0.031 [‡]
Electrolytes					
Creatinine, μmol L⁻¹		69.5 [53.5, 107]	84 [54, 118]	64 [53, 99]	0.099 [‡]
Cardiac biomarkers					
NT-proBNP, ng L⁻¹	<i>n (n missing)</i>	100 (12) 458 [198.5, 1689.5]	32 (1) 537.5 [208, 3634.2]	68 (11) 430.5 [194, 1275.2]	0.213 [‡]
Abnormal NT-proBNP^A	<i>n (n missing)</i>	100 (12) 63 (63%)	32 (1) 20 (62.5%)	68 (11) 43 (63.2%)	>0.99 [†]
hsTn I, ng L⁻¹	<i>n (n missing)</i>	64 (48) 12[4.8, 42]	24 (9) 19.5 [4.8, 42]	40 (39) 10.0 [4.8, 40]	0.605 [‡]
hsTn T, ng L⁻¹	<i>n (n missing)</i>	46 (66) 16.5 [10, 28.5]	9 (24) 18 [15, 37]	37 (42) 16 [10, 26]	0.239 [‡]
Abnormal troponin^B	<i>n (n missing)</i>	110 (2) 51 (46.4%)	33 (0) 17 (51.5%)	77 (2) 34 (44.2%)	0.535 [†]
Clinical Parameters					
HR, bpm		79 (19.9)	81.3 (21.1)	78.1 (19.5)	0.446 [#]
Rhythm	Sinus	107 (95.5%)	31 (93.9%)	76 (96.2%)	
	AF/Flutter	5 (4.5%)	2 (6.1%)	3 (3.8%)	0.630 [†]
Mean BP, mmHg	<i>n (n missing)</i>	109 (3) 80.9 (13.4)	32 (1) 77.9 (10.5)	77 (2) 82.1 (14.3)	0.089 [#]
CVP, cmH₂O	<i>n (n missing)</i>	74 (38) 7 [4, 12]	22 (11) 7.5 [6.0, 13.8]	52 (27) 7.0 [3.8, 11.2]	0.307 [‡]
Drug Administration					
Vasopressors		40 (35.7%)	18 (54.5%)	22 (27.8%)	0.010 [†]
Inotropes		1 (0.9%)	1 (3%)	0 (0%)	0.295 [†]
Anticoagulation	Prophylactic	93 (83%)	24 (72.7%)	69 (87.3%)	
	Therapeutic	17 (15.2%)	9 (27.3%)	8 (10.1%)	0.057 [†]
	None	2 (1.8%)	0 (0%)	0 (0%)	
Paralysis		52 (46.4%)	18 (54.5%)	34 (43%)	0.511 [†]
Ventilation					
FiO₂		0.6 [0.4, 0.7]	0.6 [0.5, 0.7]	0.6 [0.4, 0.7]	0.083 [‡]
Requirement for prone ventilation in previous 24 hours		44 (39.3%)	16 (48.5%)	28 (35.4%)	0.498 [†]

Plateau pressure, cmH₂O		58 (54) 24 [22, 27]	19 (14) 27 [25, 29.5]	39 (40) 24 [22, 26]	0.018 [‡]
PAP, cmH₂O	<i>n (n missing)</i>	58 (54) 25 [20, 30]	33 (0) 27 [21, 30]	76 (3) 24 [20, 28.2]	0.176 [‡]
Tidal volume, ml kg⁻¹ (PBW)	<i>n (n missing)</i>	108 (4) 7.2 (2.1)	32 (1) 7.2 (2.5)	76 (3) 7.2 (2)	0.964 [#]
P/F ratio		17 [13.6, 21.3]	15.2 [11.7, 18]	17.8 [14.3, 21.4]	0.047 [‡]
PEEP, cmH₂O	<i>n (n missing)</i>	111 (1) 9.8 (3.6)	33 (0) 10.2 (3.4)	78 (1) 9.7 (3.7)	0.447 [#]
Resp rate, minute⁻¹		24.3 (5.3)	24.8 (5.2)	24.1 (5.3)	0.489 [#]
Driving pressure, cmH₂O	<i>n (n missing)</i>	58 (54) 14.7 (7.1)	19 (14) 15.9 (5.7)	39 (40) 14.0 (7.6)	0.290 [#]
Dynamic compliance, ml cmH₂O⁻¹	<i>n (n missing)</i>	58 (54) 29.8 [20, 40]	19 (14) 21.3 [17.9, 36]	39 (40) 34.3 [22.7, 41.8]	0.082 [‡]
Murray lung injury score	<i>n (n missing)</i>	100 (12) 2.8 [2.3, 3]	31 (2) 2.8 [2.5, 3.3]	69 (10) 2.8 [2.3, 3]	0.491 [‡]

RVD defined as RV dilatation *and/or* septal flattening

Data are presented as mean (SD), median [IQR] or n (%). Data are complete unless indicated by *n (n missing)*. P-values provided are for comparisons between RVD vs no RVD. # = Student's T-test. † = Fisher's Exact test. ‡ = Wilcoxon Mann-Whitney test. Missing data indicated by *n (n missing)*.

A, NT-proBNP ≥300 ng L⁻¹

B, hsTnT ≥15 ng L⁻¹ or hsTnI ≥34 ng L⁻¹ for males; ≥16 ng L⁻¹ for females

RVD = Right Ventricular Dysfunction, RRT = Renal Replacement Therapy, BE = Base Excess, CRP = C-Reactive Protein, PT = Prothrombin Time, APTT = Activated Partial Thromboplastin Time, NT-proBNP = N-terminal pro B-type Natriuretic Peptide, hsTn = High Sensitivity Troponin, HR = Heart Rate, AF = Atrial Fibrillation, BP = Blood Pressure, CVP = Central Venous Pressure, FiO₂ = Fraction of Inspired Oxygen, PAP = Peak Airway Pressure, PBW = Predicted Body Weight, PEEP = Positive End Expiratory Pressure.

Supplementary Table 6. Logistic regression model predicting 30-day mortality adjusting for remaining variables in table

	OR (95% CI)	p-value
RV dilatation <i>and/or</i> septal flattening	1.35 (0.54, 3.46),	=0.523
Age, in years (per 5-year increase)	1.52 (1.21, 1.97),	=0.001
Female Gender	1.09 (0.44, 2.70),	=0.855
Non-white ethnicity	0.68 (0.15, 2.90),	=0.610
APACHE II score on admission to ICU (per 5-score increase)	1.30 (0.88, 1.98),	=0.191
Time from intubation to date of echo, in days (per 1-day increase)	1.02 (0.88, 1.17),	=0.826

APACHE = Acute Physiology And Chronic Health Evaluation